Bharat Parenterals Q1 FY27: Margin quality improves as subsidiaries take the growth baton

Bharat Parenterals Limited opened FY27 with a quarter that looked weaker on headline revenue but stronger on the underlying mix. Consolidated revenue for Q1 FY27 came in at ₹93.7 crore, down 19.2% year on year. EBITDA was ₹8.5 crore with a 9.1% margin versus 11.9% a year ago. Consolidated PAT was a loss of ₹3.6 crore.

The company’s own explanation frames the comparison as a contract timing issue rather than a demand shock. Q1 FY26 was the largest revenue quarter in the company’s history, driven by a large institutional order. Q1 FY27 is being compared against that outlier, where the opening tranche of a ₹210 crore order sits against its closing tranche. In that sense, the quarter is less about losing volume and more about shifting where the group’s revenue is coming from.

That shift is visible in the mix. Standalone Bharat Parenterals revenue fell sharply to ₹55.5 crore, down 41.2% year on year, while the two operating subsidiaries expanded quickly. Innoxel Lifesciences reported ₹21.4 crore of revenue, up 164.8% year on year, and Varenyam Healthcare grew 52.2% to ₹25.1 crore. Together, Innoxel and Varenyam Healthcare contributed 46% of consolidated revenue before eliminations, up from 21% a year earlier.

A quarter that traded volume for quality

The most important line in management commentary is not the revenue decline. It is the gross margin. Consolidated gross profit held flat at ₹47.4 crore even as revenue fell, because the gross margin expanded by roughly 1,000 basis points to 50.6%. The company attributes this to mix. The portion of revenue that did not repeat had materially lower profitability, while the revenue that did remain carried higher margins.

But the gross margin improvement did not fully translate into operating profit. Consolidated operating expenses increased 16.5% year on year to ₹38.9 crore and rose to 41.5% of revenue from 28.8% a year ago. Management says this increase is largely concentrated at Innoxel and Varenyam Healthcare, where the group has been building capacity and commercial infrastructure ahead of contracted forward revenue. The company’s argument is straightforward: as subsidiary revenue scales, EBITDA margins should revert toward normal.

The consolidated P&L supports the idea that operating costs are the swing factor. EBITDA declined 38% to ₹8.5 crore, while depreciation and amortisation of ₹8.7 crore kept EBIT marginally negative. PAT remained in the red at ₹3.6 crore. The earnings bridge at the entity level also shows that the consolidated loss is heavily driven by Innoxel’s loss as it moves toward commercial scale.

Segment performance: three businesses, three timelines

The group now reads like a portfolio of timelines rather than one uniform business. The standalone formulations and exports business provides the anchor cash flows. Varenyam Healthcare is building a domestic institutional franchise that already shows operating leverage. Innoxel is positioned as the regulated-market engine, but it is still absorbing fixed costs while moving from development and licensing into commercial supply.

Standalone Bharat Parenterals reported Q1 FY27 revenue of ₹55.5 crore, broadly flat sequentially versus ₹56.5 crore in Q4 FY26, but sharply lower year on year. The more encouraging signal was profitability. Standalone EBITDA margin recovered to 12.3% from near breakeven in Q4 FY26, and PAT was ₹3.7 crore with a 6.6% margin. Gross margin expanded to 39.8% from 33.4% a year ago, a 636 basis point improvement.

Operationally, the standalone business remains oriented to emerging market exports and tenders. It has presence across 40 plus countries with 350 plus product filings. The order book is stated at ₹171 crore, split across domestic tenders of ₹119 crore, exports of ₹33 crore and international tenders of ₹20 crore. The company plans FY27 capex of ₹15 crore, following FY26 capex of ₹12.84 crore. Management’s stated mission points to deeper penetration in Latin America, Southeast Asia, MENA and Africa, and an effort to scale branded business over FY27 to FY29 anchored by a Vietnam representative office.

Innoxel Lifesciences is the most important strategic asset in the investor narrative, and also the biggest near-term drag. It is a 55.9% subsidiary positioned as an innovation-driven CDMO and out-licensing platform for complex and specialty generics. It has received a USFDA Establishment Inspection Report for an inspection conducted April 28 to May 2, 2025, and it completed a FAMHP Belgium EU-GMP inspection with zero critical or major observations. These regulatory outcomes matter because they enable commercial supply into regulated markets.

In Q1 FY27, Innoxel reported revenue of ₹21.4 crore and EBITDA of negative ₹1.8 crore. EBITDA margin improved materially from the deep losses of Q1 FY26, but remained negative at -8.5%. PAT was a loss of ₹10.4 crore. The company highlights cumulative licensing revenue of ₹72.4 crore and notes 23 deals signed in FY26, with 19 active partners across the US, EU and India.

The near-term catalyst is execution. Management indicates that first commercial CMO supply begins in Q2 FY27, with two to three CMO products commercialising during the year. The FY27 plan includes 14 filings, split between own and CMO programs. The quarter also shows the volatility that comes with a licensing-heavy and project-based ramp: Q4 FY26 revenue was ₹37.5 crore with positive EBITDA, while Q1 FY27 revenue fell to ₹21.4 crore and margins slipped back into the red.

Varenyam Healthcare, a 100% subsidiary, is the cleanest growth story in the quarter. It sells branded generics through the institutional and acute hospital channel, focusing on anaesthesia, pain management and critical care. Q1 FY27 revenue was ₹25.1 crore, up 52.2% year on year and up 117.5% sequentially versus Q4 FY26. EBITDA was ₹3.1 crore with a 12.4% margin, and PAT was ₹2.8 crore.

The business already has scale indicators. It reported 211 medical representatives, a per MR per month productivity of ₹3.82 lakh, 10 owned depots and 800 plus channel partners across 26 states. It also claims coverage of 7,500 plus hospitals and references multiple corporate hospital relationships. Management’s FY27 plan calls for expanding the field force toward 250 MRs.

Strategy and context: why the map matters

Bharat Parenterals spends an unusual amount of time in the deck mapping its strategy to where growth is happening in Indian pharma. On exports, it highlights a corridor inversion in FY26 where Africa, Latin America and Europe grew while the United States declined. The company’s takeaway is that its core standalone geographies are in the faster-growing corridors. It also positions itself to benefit from a compliance-driven supply shakeout through revised Schedule M, where only around 43% of about 8,500 MSME units were compliant by the December 31, 2025 deadline.

On domestic demand, Varenyam Healthcare’s thesis is that institutions account for roughly 31% of India’s pharmaceutical market by value. With limited volume growth in the broader market, growth is concentrated in price and new launches. That aligns with its portfolio design, which emphasises specialised hospital products and first-in-India launches such as Sugammadex. The company also frames a capacity tailwind through the expansion of private hospital bed counts and the continued scale-up of publicly funded demand under PM-JAY.

Innoxel is positioned against a different set of industry facts. The group frames regulated-market sterile capacity as scarce and points to US drug shortages being heavily concentrated in injectables. It also cites the broader growth pool for CRDMO services, where India remains a small share of a large global market. For investors, the strategic point is that a USFDA EIR and EU-GMP cleared manufacturing platform is difficult to replicate quickly, but monetisation requires sustained execution and predictable commercial supply.

A fourth platform is being built for the longer term. Varenyam Bio Lifesciences is a 100% subsidiary and remains pre-revenue. It reported CWIP of ₹33.22 crore as of Q1 FY27 against a stated project budget of ₹160 crore. Borrowings were ₹7.12 crore and net worth ₹28.22 crore. The company targets commissioning in September 2027, line validation by March 2028, first filing in Q1 FY29 and first commercial supply by Q4 FY29. The intended positioning is EU-GMP targeted manufacturing for emerging regulated markets, with a pipeline sourced from Innoxel.

What to watch after Q1 FY27

The quarter is best read as a transition. Consolidated revenue declined, but the businesses that are meant to define the next phase are growing. The question is whether the cost base built at Innoxel and Varenyam Healthcare converts into higher consolidated profitability, and how quickly.

Management has laid out clear FY27 guidance by entity. Standalone Bharat Parenterals targets 10% to 15% growth and 10% to 15% EBITDA margin, and it delivered 12.3% EBITDA margin in Q1. Innoxel targets 35% to 45% growth and 20% to 25% EBITDA margin, and it delivered high growth in Q1 but remains loss-making while commercial CMO supply is yet to scale. Varenyam Healthcare targets 20% to 25% growth and 8% to 13% EBITDA margin, and it ran ahead of both in Q1.

For investors, the quarter’s theme is mix shift with execution risk. The anchor business is stabilising margins after a volatile FY26, and the domestic institutional franchise is gaining scale. The regulated-market engine is the most valuable optionality, but it must prove repeatable commercial supply and progress toward operating break-even.

If Q1 FY27 established one thing, it is that Bharat Parenterals is no longer a single-business export formulations company. It is a group balancing near-term cash generation with subsidiary investment cycles. The next few quarters will determine whether that structure starts showing consolidated operating leverage, or whether the cost of building those platforms stays ahead of revenue for longer.